cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.15102493
title: Additional file 14 of Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland

description: Additional file 14. Supplementary Table 8: Alternative splicing, EP + PR inhibitors, MSC
DOI: 10.6084/m9.figshare.15102496
title: Additional file 15 of Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland

description: Additional file 15. Supplementary Table 9: Alternative splicing, EP + PR inhibitors, LP
DOI: 10.6084/m9.figshare.15102499
title: Additional file 16 of Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland

description: Additional file 16. Supplementary Table 11: Alternative splicing, EP + PR inhibitors, LM
DOI: 10.6084/m9.figshare.15102499.v1
title: Additional file 16 of Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland

description: Additional file 16. Supplementary Table 11: Alternative splicing, EP + PR inhibitors, LM
DOI: 10.6084/m9.figshare.15102505
title: Additional file 18 of Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland

description: Additional file 18. Supplementary Table 12: RNA binding protein motifs, EP, LP
DOI: 10.6084/m9.figshare.15102502.v1
title: Additional file 17 of Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland

description: Additional file 17. Supplementary Table 11: RNA binding protein motifs, EP, MSC
DOI: 10.6084/m9.figshare.15102502
title: Additional file 17 of Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland

description: Additional file 17. Supplementary Table 11: RNA binding protein motifs, EP, MSC
DOI: 10.6084/m9.figshare.15102505.v1
title: Additional file 18 of Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland

description: Additional file 18. Supplementary Table 12: RNA binding protein motifs, EP, LP
DOI: 10.6084/m9.figshare.15102508
title: Additional file 19 of Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland

description: Additional file 19. Supplementary Table 13: RNA binding protein motifs, EP, LM
DOI: 10.6084/m9.figshare.15102514
title: Additional file 20 of Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland

description: Additional file 20. Supplementary Table 14: RNA binding protein motifs, EP + TPA, MSC
DOI: 10.6084/m9.figshare.15102508.v1
title: Additional file 19 of Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland

description: Additional file 19. Supplementary Table 13: RNA binding protein motifs, EP, LM
DOI: 10.6084/m9.figshare.15102514.v1
title: Additional file 20 of Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland

description: Additional file 20. Supplementary Table 14: RNA binding protein motifs, EP + TPA, MSC
DOI: 10.6084/m9.figshare.15102517.v1
title: Additional file 21 of Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland

description: Additional file 21. Supplementary Table 15: RNA binding protein motifs, EP + TPA, MSC
DOI: 10.6084/m9.figshare.15102517
title: Additional file 21 of Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland

description: Additional file 21. Supplementary Table 15: RNA binding protein motifs, EP + TPA, MSC
DOI: 10.6084/m9.figshare.15102520
title: Additional file 22 of Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland

description: Additional file 22. Supplementary Table 16: RNA binding protein motifs, EP + TPA, MSC
DOI: 10.6084/m9.figshare.15102523.v1
title: Additional file 23 of Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland

description: Additional file 23. Supplementary Table 17: Validated alternative splicing
DOI: 10.6084/m9.figshare.15102520.v1
title: Additional file 22 of Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland

description: Additional file 22. Supplementary Table 16: RNA binding protein motifs, EP + TPA, MSC
DOI: 10.6084/m9.figshare.15102523
title: Additional file 23 of Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland

description: Additional file 23. Supplementary Table 17: Validated alternative splicing
DOI: 10.6084/m9.figshare.15102541
title: Additional file 7 of Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland

description: Additional file 7. Supplementary Table 1: list of primers utilized
DOI: 10.6084/m9.figshare.15102541.v1
title: Additional file 7 of Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland

description: Additional file 7. Supplementary Table 1: list of primers utilized
DOI: 10.6084/m9.figshare.15102544
title: Additional file 8 of Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland

description: Additional file 8. Supplementary Table 2: List of differentially expressed genes, MSC
DOI: 10.6084/m9.figshare.15102544.v1
title: Additional file 8 of Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland

description: Additional file 8. Supplementary Table 2: List of differentially expressed genes, MSC
DOI: 10.6084/m9.figshare.15102547
title: Additional file 9 of Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland

description: Additional file 9. Supplementary Table 3: List of differentially expressed genes, LP
DOI: 10.6084/m9.figshare.15102547.v1
title: Additional file 9 of Progesterone receptor antagonists reverse stem cell expansion and the paracrine effectors of progesterone action in the mouse mammary gland

description: Additional file 9. Supplementary Table 3: List of differentially expressed genes, LP
DOI: 10.6084/m9.figshare.15102639
title: Additional file 2 of Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer

description: Additional file 2. TROG 15.03 FASTRACKII KBP Feedback Report– Patient Specific Questionnaire.
DOI: 10.6084/m9.figshare.15102642
title: Additional file 3 of Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer

description: Additional file 3. Details of case submission timelines and outcome of KBP review.
DOI: 10.6084/m9.figshare.15102642.v1
title: Additional file 3 of Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer

description: Additional file 3. Details of case submission timelines and outcome of KBP review.
DOI: 10.6084/m9.figshare.15102639.v1
title: Additional file 2 of Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer

description: Additional file 2. TROG 15.03 FASTRACKII KBP Feedback Report– Patient Specific Questionnaire.
DOI: 10.6084/m9.figshare.15102672.v1
title: Additional file 1 of Angiopoietin 1 release from human neutrophils is independent from neutrophil extracellular traps (NETs)

description: Additional file 1. Individual patient characteristics and raw data for NETs release, Ang1 and calprotectin synthesis and release from human neutrophils.
DOI: 10.6084/m9.figshare.15102672
title: Additional file 1 of Angiopoietin 1 release from human neutrophils is independent from neutrophil extracellular traps (NETs)

description: Additional file 1. Individual patient characteristics and raw data for NETs release, Ang1 and calprotectin synthesis and release from human neutrophils.
DOI: 10.6084/m9.figshare.15102726.v1
title: Additional file 2 of Reverse complementary matches simultaneously promote both back-splicing and exon-skipping

description: Additional file 2: Table S1. Strains used in this study.
DOI: 10.6084/m9.figshare.15102729.v1
title: Additional file 3 of Reverse complementary matches simultaneously promote both back-splicing and exon-skipping

description: Additional file 3: Table S2. Primers used in this study.
DOI: 10.6084/m9.figshare.15102726
title: Additional file 2 of Reverse complementary matches simultaneously promote both back-splicing and exon-skipping

description: Additional file 2: Table S1. Strains used in this study.
DOI: 10.6084/m9.figshare.15102735
title: Additional file 5 of Reverse complementary matches simultaneously promote both back-splicing and exon-skipping

description: Additional file 5: Table S4. Differential expression analysis results of linear mRNAs between the sort and the whole group by DESeq2.
DOI: 10.6084/m9.figshare.15102729
title: Additional file 3 of Reverse complementary matches simultaneously promote both back-splicing and exon-skipping

description: Additional file 3: Table S2. Primers used in this study.
DOI: 10.6084/m9.figshare.15102738
title: Additional file 6 of Reverse complementary matches simultaneously promote both back-splicing and exon-skipping

description: Additional file 6: Table S5. List of high-confidence circRNAs with numbers of BSJ reads in each sample.
DOI: 10.6084/m9.figshare.15102741
title: Additional file 7 of Reverse complementary matches simultaneously promote both back-splicing and exon-skipping

description: Additional file 7: Table S6. Differential expression analysis results of the high-confidence circRNAs between the sort and the whole group by DESeq2.
DOI: 10.6084/m9.figshare.15102732
title: Additional file 4 of Reverse complementary matches simultaneously promote both back-splicing and exon-skipping

description: Additional file 4: Table S3. List of gRNA sequences, recombinant oligos, and validation primers used for mutagenesis by CRISPR-Cas9.
DOI: 10.6084/m9.figshare.15102732.v1
title: Additional file 4 of Reverse complementary matches simultaneously promote both back-splicing and exon-skipping

description: Additional file 4: Table S3. List of gRNA sequences, recombinant oligos, and validation primers used for mutagenesis by CRISPR-Cas9.
DOI: 10.6084/m9.figshare.15102735.v1
title: Additional file 5 of Reverse complementary matches simultaneously promote both back-splicing and exon-skipping

description: Additional file 5: Table S4. Differential expression analysis results of linear mRNAs between the sort and the whole group by DESeq2.
DOI: 10.6084/m9.figshare.15102738.v1
title: Additional file 6 of Reverse complementary matches simultaneously promote both back-splicing and exon-skipping

description: Additional file 6: Table S5. List of high-confidence circRNAs with numbers of BSJ reads in each sample.
DOI: 10.6084/m9.figshare.15102741.v1
title: Additional file 7 of Reverse complementary matches simultaneously promote both back-splicing and exon-skipping

description: Additional file 7: Table S6. Differential expression analysis results of the high-confidence circRNAs between the sort and the whole group by DESeq2.
DOI: 10.6084/m9.figshare.15102804
title: Additional file 2 of Simplified binomial estimation of human malaria transmission exposure distributions based on hard classification of where and when mosquitoes are caught: statistical applications with off-the-shelf tools

description: Additional file 2: Dataset S1. An Excel® spreadsheet template for calculating individual-level estimates for the proportion of exposure of bites by Anopheles gambiae (s.l.) that would occur indoors or while asleep in the absence of any protective interventions, such as window screens or bed nets, in the Tanzanian city of Dar es Salaam [20], as illustrated in Additional file 1: Poster S1. This example is populated with an anonymized sample of questionnaire data describing the times residents reported having gone indoors for the evening, gone to sleep for the night, woke up in the morning and left the house in the morning, as well as published patterns of vector biting activity as measured by human landing catch in parts of Dar es Salaam with vector densities that were high enough to measure [20].
DOI: 10.6084/m9.figshare.15102804.v1
title: Additional file 2 of Simplified binomial estimation of human malaria transmission exposure distributions based on hard classification of where and when mosquitoes are caught: statistical applications with off-the-shelf tools

description: Additional file 2: Dataset S1. An Excel® spreadsheet template for calculating individual-level estimates for the proportion of exposure of bites by Anopheles gambiae (s.l.) that would occur indoors or while asleep in the absence of any protective interventions, such as window screens or bed nets, in the Tanzanian city of Dar es Salaam [20], as illustrated in Additional file 1: Poster S1. This example is populated with an anonymized sample of questionnaire data describing the times residents reported having gone indoors for the evening, gone to sleep for the night, woke up in the morning and left the house in the morning, as well as published patterns of vector biting activity as measured by human landing catch in parts of Dar es Salaam with vector densities that were high enough to measure [20].
DOI: 10.6084/m9.figshare.15102810
title: Additional file 3 of Simplified binomial estimation of human malaria transmission exposure distributions based on hard classification of where and when mosquitoes are caught: statistical applications with off-the-shelf tools

description: Additional file 3: Dataset S2. An example of a sample size calculation for a nationally representative survey of the proportion of human exposure to malaria vectors occurring indoors in the United Republic of Tanzania, using an Excel® spreadsheet template to apply Eq. 4 of the classic paper by Hayes and Bennett [27], as explained in Box 2 and illustrated in Fig. 2 and Additional file 1: Poster S1.
DOI: 10.6084/m9.figshare.15102810.v1
title: Additional file 3 of Simplified binomial estimation of human malaria transmission exposure distributions based on hard classification of where and when mosquitoes are caught: statistical applications with off-the-shelf tools

description: Additional file 3: Dataset S2. An example of a sample size calculation for a nationally representative survey of the proportion of human exposure to malaria vectors occurring indoors in the United Republic of Tanzania, using an Excel® spreadsheet template to apply Eq. 4 of the classic paper by Hayes and Bennett [27], as explained in Box 2 and illustrated in Fig. 2 and Additional file 1: Poster S1.
DOI: 10.6084/m9.figshare.15102850
title: Additional file 1 of Digital learning in medical education: comparing experiences of Malaysian and Japanese students

description: Additional file 1.
DOI: 10.6084/m9.figshare.15102850.v1
title: Additional file 1 of Digital learning in medical education: comparing experiences of Malaysian and Japanese students

description: Additional file 1.
DOI: 10.6084/m9.figshare.15040485
title: Data for "Restoration of a declining foundation plant species: testing the roles of competitor suppression, fire reintroduction and herbivore exclusion"

description: Full data set from field and germination trials used in production of results.
DOI: 10.6084/m9.figshare.15040485.v1
title: Data for "Restoration of a declining foundation plant species: testing the roles of competitor suppression, fire reintroduction and herbivore exclusion"

description: Full data set from field and germination trials used in production of results.
DOI: 10.6084/m9.figshare.15102906
title: Additional file 2 of Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models

description: Additional file 2. Table S1. Heat map ranking the total phosphopeptide intensity for specific kinases across the 19 PDX samples. Table S2. Heat map ranking individual phosphopeptide intensity for specific kinases across the 19 PDX samples.
DOI: 10.6084/m9.figshare.15102906.v1
title: Additional file 2 of Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models

description: Additional file 2. Table S1. Heat map ranking the total phosphopeptide intensity for specific kinases across the 19 PDX samples. Table S2. Heat map ranking individual phosphopeptide intensity for specific kinases across the 19 PDX samples.
DOI: 10.6084/m9.figshare.15102915
title: Additional file 5 of Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models

description: Additional file 5. Table S3. MS data for both TiO2 and pTyr enrichment workflows applied to AZD4547-treated KCC_P_4043.
DOI: 10.6084/m9.figshare.15102921
title: Additional file 7 of Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models

description: Additional file 7. Table S5. SNVs in KCC_P_4043 tumor.
DOI: 10.6084/m9.figshare.15102915.v1
title: Additional file 5 of Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models

description: Additional file 5. Table S3. MS data for both TiO2 and pTyr enrichment workflows applied to AZD4547-treated KCC_P_4043.
DOI: 10.6084/m9.figshare.15102918
title: Additional file 6 of Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models

description: Additional file 6. Table S4. Bioinformatic analysis of MS data for drug-treated KCC_P_4043.
DOI: 10.6084/m9.figshare.15102918.v1
title: Additional file 6 of Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models

description: Additional file 6. Table S4. Bioinformatic analysis of MS data for drug-treated KCC_P_4043.
DOI: 10.6084/m9.figshare.15102927
title: Additional file 8 of Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models

description: Additional file 8. Table S6. MS data for both TiO2 and pTyr enrichment workflows applied to BLU9931-treated HCI-009.
DOI: 10.6084/m9.figshare.15102921.v1
title: Additional file 7 of Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models

description: Additional file 7. Table S5. SNVs in KCC_P_4043 tumor.
DOI: 10.6084/m9.figshare.15102930
title: Additional file 9 of Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models

description: Additional file 9. Table S7. Top 20 downregulated KEGG and Reactome pathways for phospho-tyrosine or TiO2 enrichment in BLU9931-treated HCI-009.
DOI: 10.6084/m9.figshare.15102927.v1
title: Additional file 8 of Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models

description: Additional file 8. Table S6. MS data for both TiO2 and pTyr enrichment workflows applied to BLU9931-treated HCI-009.
DOI: 10.6084/m9.figshare.15102930.v1
title: Additional file 9 of Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models

description: Additional file 9. Table S7. Top 20 downregulated KEGG and Reactome pathways for phospho-tyrosine or TiO2 enrichment in BLU9931-treated HCI-009.
DOI: 10.6084/m9.figshare.15102957
title: Additional file 1 of N2O emission and its influencing factors in subtropical streams, China

description: Additional file 1: Fig. S1. amoA genes abundance in the Jinshui River and Qi River. Vertical bar denote SE of triplicate samples (Zhao et al. 2020). The genes primers were shown in Table S7. Fig. S2. nirK gene abundance in the Jinshui River and Qi River. Vertical bar denote SE of triplicate samples (The data have not yet been published). The measured method was the same as amoA genes. The gene primer was shown in Table S7. Fig. S3. nirS genes abundance in the Jinshui River and Qi River. Vertical bar denote SE of triplicate samples (The data have not yet been published). The measured method was the same as amoA genes. The gene primer was shown in Table S7. Fig. S4. nosZ genes abundance in the Jinshui River and Qi River. Vertical bar denote SE of triplicate samples (The data have not yet been published). The measured method was the same as amoA genes. The gene primer was shown in Table S7. Fig. S5. Potential nitrification rates in the Jinshui River and Qi River. Vertical bar denote SE of triplicate samples (Zhao et al. 2020). Fig. S6. Potential nitrification rates in the Jinshui River and Qi River. Vertical bar denote SE of triplicate samples (The data have not yet been published). Table S1. The land use attribute table of the Jinshui River and Qi River. Table S2. Wind speed (m/s) at 2 m above water surface of Jinshui River and Qi River. Table S3. Pearson’s correlation analyses between N2O concentration and physicochemical variables. * represent P &lt; 0.05, **represent P
DOI: 10.6084/m9.figshare.15102946
title: Additional file 10 of Predicted antiviral drugs Darunavir, Amprenavir, Rimantadine and Saquinavir can potentially bind to neutralize SARS-CoV-2 conserved proteins

description: Additional file 1: S10. List of drug binding hits for 6VWW-NSP15.
DOI: 10.6084/m9.figshare.15102949
title: Additional file 11 of Predicted antiviral drugs Darunavir, Amprenavir, Rimantadine and Saquinavir can potentially bind to neutralize SARS-CoV-2 conserved proteins

description: Additional file 1: S11. List of drug binding hits for 7BQ7-NSP16-10.
DOI: 10.6084/m9.figshare.15102946.v1
title: Additional file 10 of Predicted antiviral drugs Darunavir, Amprenavir, Rimantadine and Saquinavir can potentially bind to neutralize SARS-CoV-2 conserved proteins

description: Additional file 1: S10. List of drug binding hits for 6VWW-NSP15.
DOI: 10.6084/m9.figshare.15102949.v1
title: Additional file 11 of Predicted antiviral drugs Darunavir, Amprenavir, Rimantadine and Saquinavir can potentially bind to neutralize SARS-CoV-2 conserved proteins

description: Additional file 1: S11. List of drug binding hits for 7BQ7-NSP16-10.
DOI: 10.6084/m9.figshare.15102952
title: Additional file 1 of Predicted antiviral drugs Darunavir, Amprenavir, Rimantadine and Saquinavir can potentially bind to neutralize SARS-CoV-2 conserved proteins

description: Additional file 1: S1. List of drug binding hits for 7K3N –NSP1.
DOI: 10.6084/m9.figshare.15102952.v1
title: Additional file 1 of Predicted antiviral drugs Darunavir, Amprenavir, Rimantadine and Saquinavir can potentially bind to neutralize SARS-CoV-2 conserved proteins

description: Additional file 1: S1. List of drug binding hits for 7K3N –NSP1.
DOI: 10.6084/m9.figshare.15102955.v1
title: Additional file 2 of Predicted antiviral drugs Darunavir, Amprenavir, Rimantadine and Saquinavir can potentially bind to neutralize SARS-CoV-2 conserved proteins

description: Additional file 1: S2. List of drug binding hits for 6WEY-NSP3.